Indivior: Still Attractive After FY25 Earnings Beat

Indivior has rallied over 300% since 2024 lows and is maintained as a 'buy' at a $3.7bn market cap. Management targets 8% Sublocade sales growth in 2026 and 48% adjusted EBITDA margins; valuation is attractive at sub-10x NTM EV/EBITDA with ~10% FCF yield. A $400m buyback for 2026–2027, together with Sublocade market-share stability, cost controls and shareholder activism, supports the bullish investment case.

Analysis

The most durable winner from the current move is not just the equity but the ecosystem that supports long‑acting injectable opioid treatments: specialty pharmacies, cold‑chain logistics providers, and device/component suppliers for depot formulations should see steady volume and pricing power if unit growth holds. Conversely, broad‑based generic suppliers and low‑touch treatment channels will be disadvantaged as payers and physicians consolidate around branded, long‑acting solutions; that structural share shift can raise barriers to entry by increasing distribution complexity and stickiness for incumbents.

Key tail risks cluster around three timelines. Over the next 3–12 months, execution risks dominate: missed quarterly cadence on unit trends or slower buyback deployment would compress sentiment quickly. In a 12–36 month window, ANDA/patent litigation or a competitor launching a clinically equivalent long‑acting buprenorphine (or a lower‑cost alternative preferred by Medicaid formularies) is the main structural downside. Regulatory or safety signals remain low‑probability but high‑impact black swans that would reprice the story in days.

The consensus is underweighting the asymmetry created by float shrinkage and concentrated activist influence: a modest operational miss could trigger outsized price moves because liquidity is thinner, while continued steady prints could drive multiple expansion faster than fundamentals alone justify. That dichotomy creates a tradeable risk/reward where disciplined position sizing and hedges capture upside from execution and activism while capping downside from binary regulatory or competitive shocks.

Key Decisions for Investors

• Long INDV equity (initiate 1–2% portfolio weight) on confirmation of sequential Sublocade unit growth in the next quarterly print; target +35–50% in 12 months, hard stop at -15% from entry to respect float/liquidity risk.
• Directional options: buy a 12–18 month call‑spread to bias upside while limiting capital at risk (buy 20% OTM calls, sell 60% OTM calls); max premium ≈ 5–8% of notional, upside capped but delivers ~3:1+ payback if growth persists.
• Pair trade to isolate franchise risk: long INDV / short ALKS (equal dollar) for 6–12 months to isolate long‑acting OUD exposure versus broader neuro/adhd exposure; tighten stops to 10% on either leg and rebalance after each quarterly print.
• Event hedges: allocate 1–2% of position value to short‑dated (1–3 month) puts around earnings windows to protect against binary regulatory/earnings misses; unwind after confirmed sequence of prints or activist milestones.